Christoph Eberle, PhD

Christoph Eberle, Ph.D. currently leads the Discovery Immunoanalytical team at Charles River’s Shrewsbury facility. He joined the organization 2017 at the Worcester site, where he established the Flow Cytometry Core. Trained as biochemist, he specialized in cell-based assay development and fit-for-purpose validation across pre-clinical and clinical operations. In his present role, he oversees immunophenotyping of tissue and blood samples collected from various mouse models (syngeneic and humanized) for tumor microenvironment characterization (TME). Additionally, the scope of his team’s project work includes T-cell isolations for adoptive transfers, gene expression analysis by qPCR and immunoassay method development on various protein detection platforms such MSD and Gyrolab. He regularly liaises with clients to provide PD study management, scientific discussion, data analysis and interpretation. Dr. Eberle independently has been contributing to business development and strategic efforts for the Worcester Discovery site. Since 2019 he has been collaborating with the Research Models and Services (RMS) business unit to support establishing the immune humanized model portfolio.

Dr. Eberle completed his entire education in Germany. He holds a Bachelor's and Master's degree in Biochemistry from the University of Bayreuth. He later pursued his Ph.D. studies at the University of Bremen under the tutelage of Franz Peter Montforts focused on the synthesis and electrochemistry of novel porphyrin-fullerene dyads, graduating magna cum laude in 2008. Subsequently, a postdoctoral research stay brought him to Dartmouth College in the United States. Dr. Eberle maintains a professional membership with the Institute of Clinical Research (ICR) in the United Kingdom and is also involved with the International Society for Advancement of Cytometry (ISAC). Prior to joining Charles River in 2017, he held scientific positions at Envigo, Eurofins Central Laboratory and the University Medical Center Göttingen (UMG).